Top

Published in:

01-12-2021 | Ticagrelor | Research article

Coronary artery bypass graft surgery in patients on ticagrelor therapy is not associated with adverse perioperative outcomes

Authors: Sammer Diab, Mattan Arazi, Leonid Sternik, Ehud Raanani, Erez Kachel, Liza Grosman-Rimon, Amjad Shalabi, Offer Amir, Shemy Carasso

Published in: Journal of Cardiothoracic Surgery | Issue 1/2021

Abstract

Background

Management of patients treated with Ticagrelor is challenging, as stopping Ticagrelor prior to coronary bypass graft surgery (CABG) may increase the risk of acute stent thrombosis. The aim of the study was to compare bleeding complications in patients treated with ticagrelor combined with acetylsalicylic acid (ASA) versus ASA alone until 1 day before surgery.

Methods

Bleeding complications, defined as the composite of red blood cell transfusion ≥1000 ml, chest drainage ≥2000 ml, and bleeding requiring surgical re-exploration, were compared in 161 patients, with 101 on preoperative acetylsalicylic acid (ASA) alone (group A) and 65 on ticagrelor + ASA (group B).

Results

There were no differences in bleeding complications between the two groups (26% vs. 27% in group A and B, respectively), with similar chest drainage in the first 24 h (569 ± 393 ml and 649 ± 427 ml, respectively).

Conclusions

Continuing ticagrelor until coronary artery bypass surgery was not associated with increased bleeding complications, suggesting that continued management with ticagrelor until surgery may be safe.

Gielen CL, Bruggemans EF, Stijnen T, et al. Stopping antiplatelet medication before coronary artery bypass graft surgery: is there an optimal timing to minimize bleeding? Eur J Cardiothorac Surg. 2015;48(4):e64–70. https://doi.org/10.1093/ejcts/ezv269.CrossRefPubMed

Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. Esc guidelines for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation: the task force for the management of acute coronary syndromes (acs) in patients presenting without persistent st-segment elevation of the european society of cardiology (esc). Eur Heart J. 2011;32(23):2999–3054. https://doi.org/10.1093/eurheartj/ehr236.CrossRefPubMed

Angiolillo DJ, Firstenberg MS, Price MJ, Tummala PE, Hutyra M, Welsby IJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA. 2012;307(3):265–74. https://doi.org/10.1001/jama.2011.2002.CrossRefPubMedPubMedCentral

Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 esc guidelines for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation of the european society of cardiology (esc). Eur Heart J. 2016;37(3):267–315. https://doi.org/10.1093/eurheartj/ehv320.CrossRefPubMed

Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 aha/acc guideline for the management of patients with non-st-elevation acute coronary syndromes: a report of the american college of cardiology/american heart association task force on practice guidelines. J Am Coll Cardiol. 2014;64(24):e139–228. https://doi.org/10.1016/j.jacc.2014.09.017.CrossRefPubMed

Montalescot G, van’t Hof AW. Prehospital ticagrelor in st-segment elevation myocardial infarction. N Engl J Med. 2014;371(24):2339.PubMed

Subiakto I. Asrar ul Haq M, Van Gaal WJ. Bleeding risk and incidence in real world percutaneous coronary intervention patients with ticagrelor. Heart Lung Circ. 2015;24(4):404–6. https://doi.org/10.1016/j.hlc.2014.10.006.CrossRefPubMed

Hansson EC, Rexius H, Dellborg M, Albertsson P, Jeppsson A. Coronary artery bypass grafting-related bleeding complications in real-life acute coronary syndrome patients treated with clopidogrel or ticagrelor. Eur J Cardiothorac Surg. 2014;46(4):699–705; discussion 705. https://doi.org/10.1093/ejcts/ezt662.CrossRefPubMed

DiNicolantonio JJ, D'Ascenzo F, Tomek A, Chatterjee S, Niazi AK, Biondi-Zoccai G. Clopidogrel is safer than ticagrelor in regard to bleeds: a closer look at the Plato trial. Int J Cardiol. 2013;168(3):1739–44. https://doi.org/10.1016/j.ijcard.2013.06.135.CrossRefPubMed

10.

Bonhomme F, Fontana P, Reny JL. How to manage prasugrel and ticagrelor in daily practice. Eur J Intern Med. 2014;25(3):213–20. https://doi.org/10.1016/j.ejim.2014.01.016.CrossRefPubMed

11.

Held C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the Plato (platelet inhibition and patient outcomes) trial. J Am Coll Cardiol. 2011;57(6):672–84. https://doi.org/10.1016/j.jacc.2010.10.029.CrossRefPubMed

12.

Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the premier registry. Circulation. 2006;113(24):2803–9. https://doi.org/10.1161/CIRCULATIONAHA.106.618066.CrossRefPubMed

13.

Zwart B, Godschalk TC, Kelder JC, Ten Berg JM. High risk of stent thrombosis in the first 6 months after coronary stenting: do not discontinue clopidogrel early after acs. J Interv Cardiol. 2017;30(5):421–6. https://doi.org/10.1111/joic.12413.CrossRefPubMed

14.

Vivacqua A, Koch CG, Yousuf AM, Nowicki ER, Houghtaling PL, Blackstone EH, et al. Morbidity of bleeding after cardiac surgery: is it blood transfusion, reoperation for bleeding, or both? Ann Thorac Surg. 2011;91(6):1780–90. https://doi.org/10.1016/j.athoracsur.2011.03.105.CrossRefPubMed

15.

Fitchett D, Eikelboom J, Fremes S, Mazer D, Singh S, Bittira B, et al. Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian cardiovascular society. Can J Cardiol. 2009;25(12):683–9. https://doi.org/10.1016/S0828-282X(09)70527-6.CrossRefPubMedPubMedCentral

16.

Kremke M, Gissel MS, Jensen MJ, Thomassen SA, Jakobsen CJ. The association between a three-day ticagrelor discontinuation and perioperative bleeding complications. Eur J Cardiothorac Surg. 2019;55(4):714–20. https://doi.org/10.1093/ejcts/ezy355.CrossRefPubMed

17.

Malm CJ, Hansson EC, Akesson J, et al. Preoperative platelet function predicts perioperative bleeding complications in ticagrelor-treated cardiac surgery patients: a prospective observational study. Br J Anaesth. 2016;117(3):309–15. https://doi.org/10.1093/bja/aew189.CrossRefPubMed

18.

Tomsic A, Schotborgh MA, Manshanden JS, Li WW, de Mol BA. Coronary artery bypass grafting-related bleeding complications in patients treated with dual antiplatelet treatment. Eur J Cardiothorac Surg. 2016;50(5):849–56. https://doi.org/10.1093/ejcts/ezw149.CrossRefPubMed

19.

Hansson EC, Jideus L, Aberg B, et al. Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide study. Eur Heart J. 2016;37(2):189–97. https://doi.org/10.1093/eurheartj/ehv381.CrossRefPubMed

20.

Weidinger F. Discontinuation of p2y12 antagonists before coronary bypass surgery: is 5 days really required? Eur Heart J. 2016;37(2):198–9. https://doi.org/10.1093/eurheartj/ehv469.CrossRefPubMed

21.

Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: Acc/aha guidelines for the management of patients with st-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and acc/aha/scai guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the american college of cardiology foundation/american heart association task force on practice guidelines. J Am Coll Cardiol. 2009;54(23):2205–41. https://doi.org/10.1016/j.jacc.2009.10.015.CrossRefPubMed

22.

Miceli A, Duggan SM, Aresu G, et al. Combined clopidogrel and aspirin treatment up to surgery increases the risk of postoperative myocardial infarction, blood loss and reoperation for bleeding in patients undergoing coronary artery bypass grafting. Eur J Cardiothorac Surg. 2013;43(4):722–8. https://doi.org/10.1093/ejcts/ezs369.CrossRefPubMed

23.

Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 esc focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with eacts: the task force for dual antiplatelet therapy in coronary artery disease of the european society of cardiology (esc) and of the european association for cardio-thoracic surgery (eacts). Eur Heart J. 2018;39(3):213–60. https://doi.org/10.1093/eurheartj/ehx419.CrossRefPubMed

24.

Sousa-Uva M, Head SJ, Milojevic M, et al. 2017 eacts guidelines on perioperative medication in adult cardiac surgery. Eur J Cardiothorac Surg. 2018;53(1):5–33. https://doi.org/10.1093/ejcts/ezx314.CrossRefPubMed

25.

Schaefer A, Sill B, Schoenebeck J, Schneeberger Y, Kubik M, Reichenspurner H, et al. Preoperative ticagrelor administration leads to a higher risk of bleeding during and after coronary bypass surgery in a case-matched analysis. Interact Cardiovasc Thorac Surg. 2016;22(2):136–40. https://doi.org/10.1093/icvts/ivv296.CrossRefPubMed

26.

Mehta SR, Yusuf S. The clopidogrel in unstable angina to prevent recurrent events (cure) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J. 2000;21(24):2033–41. https://doi.org/10.1053/euhj.2000.2474.CrossRefPubMed

27.

Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG, et al. 2011 accf/aha guideline for coronary artery bypass graft surgery. A report of the american college of cardiology foundation/american heart association task force on practice guidelines. Developed in collaboration with the american association for thoracic surgery, society of cardiovascular anesthesiologists, and society of thoracic surgeons. J Am Coll Cardiol. 2011;58(24):e123–210. https://doi.org/10.1016/j.jacc.2011.08.009.CrossRefPubMed

28.

Zhang ZZ, Zhang SZ, Zhou HM, Fan YQ, Liu MH, Zhong XB, et al. A systematic review of guidelines for dual antiplatelet therapy in coronary artery bypass graft. Eur J Clin Investig. 2021;51(1):e13405. https://doi.org/10.1111/eci.13405.CrossRef

29.

Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 esc/eacts guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87–165. https://doi.org/10.1093/eurheartj/ehy394.CrossRefPubMed

30.

Li YH, Wang YC, Wang YC, Liu JC, Lee CH, Chen CC, et al. Guidelines of the Taiwan society of cardiology, Taiwan society of emergency medicine and Taiwan society of cardiovascular interventions for the management of non st-segment elevation acute coronary syndrome. J Formos Med Assoc. 2018;117(9):766–90. https://doi.org/10.1016/j.jfma.2018.06.002.CrossRefPubMed

31.

Nakamura M, Kimura K, Kimura T, Ishihara M, Otsuka F, Kozuma K, et al. Jcs 2020 guideline focused update on antithrombotic therapy in patients with coronary artery disease. Circ J. 2020;84(5):831–65. https://doi.org/10.1253/circj.CJ-19-1109.CrossRefPubMed

32.

Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG, et al. 2011 accf/aha guideline for coronary artery bypass graft surgery: executive summary: a report of the american college of cardiology foundation/american heart association task force on practice guidelines. Circulation. 2011;124(23):2610–42. https://doi.org/10.1161/CIR.0b013e31823b5fee.CrossRefPubMed

33.

Ferraris VA, Saha SP, Oestreich JH, Song HK, Rosengart T, Reece TB, et al. 2012 update to the society of thoracic surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations. Ann Thorac Surg. 2012;94(5):1761–81. https://doi.org/10.1016/j.athoracsur.2012.07.086.CrossRefPubMed

34.

O'Gara PT, Kushner FG, Ascheim DD, Casey de Jr, Chung MK, de Lemos JA, et al. 2013 accf/aha guideline for the management of st-elevation myocardial infarction: a report of the american college of cardiology foundation/american heart association task force on practice guidelines. Circulation. 2013;127(4):e362–425. https://doi.org/10.1161/CIR.0b013e3182742cf6.CrossRefPubMed

35.

Mehta SR, Bainey KR, Cantor WJ, Lordkipanidzé M, Marquis-Gravel G, Robinson SD, et al. 2018 Canadian cardiovascular society/Canadian association of interventional cardiology focused update of the guidelines for the use of antiplatelet therapy. Can J Cardiol. 2018;34(3):214–33. https://doi.org/10.1016/j.cjca.2017.12.012.CrossRefPubMed

Title: Coronary artery bypass graft surgery in patients on ticagrelor therapy is not associated with adverse perioperative outcomes
Authors: Sammer Diab
Mattan Arazi
Leonid Sternik
Ehud Raanani
Erez Kachel
Liza Grosman-Rimon
Amjad Shalabi
Offer Amir
Shemy Carasso
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Ticagrelor
Acetylsalicylic Acid
Acute Coronary Syndrome
Acetylsalicylic Acid
CABG
CABG
Published in: Journal of Cardiothoracic Surgery / Issue 1/2021
Electronic ISSN: 1749-8090
DOI: https://doi.org/10.1186/s13019-021-01521-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Coronary artery bypass graft surgery in patients on ticagrelor therapy is not associated with adverse perioperative outcomes

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Histological regional analysis of the aortic root and thoracic ascending aorta: a complete analysis of aneurysms from root to arch

Clinical analysis of redo aortic root replacement after cardiac surgery: a retrospective study

Posterior pericardiotomy to prevent new-onset atrial fibrillation after coronary artery bypass grafting: a systematic review and meta-analysis of 10 randomized controlled trials

Literature-based considerations regarding organizing and performing cardiac surgery against the backdrop of the coronavirus pandemic

Significance of preoperative left ventricular ejection fraction in 5-year outcome after isolated CABG

Research on clinical characteristics and prognostic analysis of heparin-induced thrombocytopenia after surgery for acute type a aortic dissection